Table 1.
Baseline characteristics in the mycophenolate mofetil (MMF), recombinant human relaxin (Relaxin), d-penicillamine (d-pen) and oral bovine type I collagen (Collagen) groups
| Variable | MMF (n=98) | Relaxin (n=231) | d-Pen (n=134) | Collagen (n=168) |
|---|---|---|---|---|
| Age (years) | 48.4±11.1 (1.00) | 47.3±10.3 (0.387) | 43.7±12.4 (0.003) | 50.8±12.2 (0.111) |
| Female, % (p value) | 83 (1.00) | 85.2 (0.663) | 77.6 (0.436) | 79.2 (0.595) |
| Race | ||||
| Caucasian, % (p value) | 76 (1.00) | 74 (0.885) | 67.9 (0.265) | 76.2 (0.900) |
| African-American, % (p value) | 14 (1.00) | 13.3 (0.973) | 19.4 (0.399) | 16.1 (0.831) |
| Other, % (p value) | 8 (1.00) | 12.8 (0.288) | 12.7 (0.377) | 7.7 (0.901) |
| Mean disease duration (months) | 21.9±27.6 (1.00) | 26.4±16.4 (0.068) | 9.5±4.1 (<0.001) | 41.8±31.9 (<0.001) |
| Modified Rodnan skin score (0–51) | 24.4±9.5 (1.00) | 27.3±6.9 (0.001) | 21.0±8.0 (0.006) | 26.1±7.8 (0.079) |
| Health Assessment Questionnaire Disability Index (0–3) | 1.10±0.64 (1.00) | 1.18±0.71 (0.337) | 1.04±0.67 (0.493) | 1.22±0.72 (0.173) |
| Antibody profile | ||||
| Anti-centromere (ACA) (94/98 tested), n (%) | 2 (2) | |||
| Anti-topoisomerase antibody (SCL-70) (94/98 tested), n (%) | 24 (24) | |||
| Antinuclear antibody (ANA) + nucleolar (SCL-70 negative) (73/98 tested), n (%) | 26 (27) |
Values are mean±SD (p value) unless stated otherwise.